Takeda Pharmaceutical saw the highest growth of 1.19% in patent filings in May and 1.12% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.76% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of Takeda Pharmaceutical‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Takeda Pharmaceutical has been focused on protecting inventions in United States(US) with 82 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 28% grants. The United States(US), World Intellectual Property Organization(WIPO), Japan(JP), and European Patent Office(EPO) patent Office are among the top ten patent offices where Takeda Pharmaceutical is filings its patents. Among the top granted patent authorities, Takeda Pharmaceutical has 28% of its grants in United States(US), 12% in European Patent Office(EPO) and 11% in Japan(JP).
Roche and Sanofi could be the strongest competitors for Takeda Pharmaceutical
In terms of grant share, Takeda Pharmaceutical stands in sixth position among its competitors. Roche and Sanofi secured the top positions according to recent patent publication data.
Patents related to rare diseases and cell & gene therapy lead Takeda Pharmaceutical's portfolio
Takeda Pharmaceutical has the highest number of patents in rare diseases followed by, cell & gene therapy and climate change. For rare diseases, nearly 51% of patents were filed and 40% of patents were granted in Q2 2024.
Depression related patents lead Takeda Pharmaceutical portfolio followed by hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency), and alzheimer's disease
Takeda Pharmaceutical has highest number of patents in depression followed by hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency), alzheimer's disease, dengue fever, and bipolar disorder (manic depression). For depression, nearly 2% of patents were filed and 3% of patents were granted in Q2 2024.
For comprehensive analysis of Takeda Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
